Recce Pharmaceuticals (ASX:RCE) UTI treatment shows strong results in animal trials
- Synthetic antibiotic company Recce Pharmaceuticals (RCE) has received positive animal trial data for its kidney infection and UTI treatment
- The trial in rats showed the RECCE 327 antibiotic significantly reduced the level of e-coli bacteria in both the kidneys and the bladder
- E-coli is a bacteria often responsible for urinary tract infections, or UTIs, which can progress to kidney infections and even blood poisoning
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
-0.005(1.28%) |
Mkt cap ! $111.3M | |||
| Open | High | Low | Value | Volume |
| 38.5¢ | 38.5¢ | 37.0¢ | $21.54K | 57.86K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3248 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 49884 | 1 |
View Market Depth
| Last trade - 14.27pm 30/07/2025 (20 minute delay) ? |
| RCE (ASX) Chart |